Compare Devon Energy Corp (DVN) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Devon Energy Corp vs Tango Therapeutics Inc. — how do they compare? Devon Energy Corp trades at $50.23 (market cap $55.23B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Devon Energy Corp is far larger — about 14.7× Tango Therapeutics Inc.'s market cap, and Devon Energy Corp pays a 2.55% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Devon Energy Corp for 136 Days and Tango Therapeutics Inc. for 0 Days on average.
| DVN | TNGX | |
|---|---|---|
Market Cap | $55.23B | $3.75B |
Volume | 10,032,111 | 9,619,106 |
Sector | Energy | Health |
52-Week High | $52.07 | $32.90 |
52-Week Low | $31.74 | $7.50 |
Typical Hold Time | 136 Days | 0 Days |
Enterprise Value | $65.97B | $2.77B |
Dividend Yield | 2.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $50.21, up 2.55% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $62.44 implying significant upside. Recent financials show revenue of $17.19B in 2025 with a net income margin of 16.67%, while valuation ratios like a P/E of 10.92 appear attractive. Activist investor Toms Capital is urging strategic review, including a potential sale, as highlighted in recent news (CNBC, 2026-09-23).
The outlook is positive given strong analyst support (72% buy ratings) and projected 2026 revenue growth to $19.7B. Key risks include oil price volatility and execution of potential asset sales. The stock presents a value opportunity with upside to price targets, though dependent on commodity markets and corporate strategy developments.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
